A method for producing a radioactive metal complex includes a step of allowing a radioactive metal to react with DOTA or a derivative thereof as a ligand in a reaction liquid to form a radioactive metal complex. The reaction liquid contains water, a buffer, and a water-soluble organic solvent. The radioactive metal is .sup.89Zr or .sup.225Ac. The ligand may have, in the structure thereof, a group to which a peptide is linked. The content of the water-soluble organic solvent in the reaction liquid is preferably 2% by volume or more and 50% by volume or less. The radioactive metal is preferably allowed to react with the ligand in the reaction liquid at 30° C. or higher and 80° C. or lower.

Metal-organic framework materials (MOFs) are highly porous entities comprising a multidentate organic ligand coordinated to multiple metal centers, typically as a coordination polymer. MOFs may comprise a plurality of metal centers, and a multidentate organic ligand coordinated via at least two binding sites to the plurality of metal centers to define an at least partially crystalline network structure having a plurality of internal pores, and in which the multidentate organic ligand comprises first and second binding sites bridged together with a third binding site comprising a diimine moiety. The multidentate organic ligand may comprise a reaction product of a vicinal dicarbonyl compound and an amine-substituted salicylic acid to define the first, second and third binding sites. Particular MOFs may comprise 5,59′-(((1E,2E)-ethane-1,2-diylidene)bis-(azaneylylidene))bis(2-hydroxybenzoic acid) as a multidentate organic ligand.

The present invention provides a method for preparing a cyclic carbonate, which has the advantages of high yield, mild reaction conditions, high catalytic efficiency under room temperature and 1 atm pressure conditions, and wide substrate scopes. It is not only suitable for monosubstituted epoxides, but also suitable for disubstituted epoxides. The method comprises the step of reacting epoxides of Formula (I) with carbon dioxide in the presence of a quaternary ammonium salt and a catalyst, to obtain a cyclic carbonate of Formula (II). The reaction formula is: ##STR00001##

A lithium ion secondary battery includes a cathode, an anode, and an electrolytic solution. The anode includes a cyclic compound and the cyclic compound includes one or more of a first cyclic compound, a second cyclic compound, and a third cyclic compound.

An electrode material and a lithium-ion energy storage device are provided. The electrode material includes at least one material selected from the following structures: a Keplerate-type polyoxometalate containing molybdenum and iron; a Keplerate-type polyoxometalate containing molybdenum and vanadium; a bi-capped Keggin-type polyoxometalate containing vanadium; and a polyoxometalate containing vanadium and a transition metal, wherein the transition metal is nickel, cobalt, iron, or manganese. A lithium-ion energy storage device having the above electrode materials may still maintain higher capacity at higher current density, and may still maintain the original capacity after many cycles.

Mixed ligand phosphinogold(I) complexes as anticancer agents. The gold(I) ion of the complexes is coordinated to a phosphine and a dithiocarbamate or halogen ligand. Also described are a pharmaceutical composition incorporating the phosphinogold(I) complex, a method of synthesizing the phosphinogold(I) complex, and a method of treating cancer. The phosphinogold(I) complexes exhibit potent cytotoxicity against lung, cervical, and liver cancer cells.

A trichlorogermanide of formula (I): [R.sub.4N]/[R.sub.4P]Cl[GeCl.sub.3] (I), where R is Me, Et, iPr, nBu, or Ph, tris(trichlorosilyl)germanide of formula (II): [R.sub.4N]/[R.sub.4P][Ge(SiCl.sub.3).sub.3] (II), where R is Me, Et, iPr, nBu, or Ph, a tris(trichlorosilyl)germanide adduct of GaCl.sub.3 of formula (III): [Ph.sub.4P][Ge(SiCl.sub.3).sub.3*GaCl.sub.3], and a tris(trichlorosilyl)germanide adduct of BBr.sub.3 of formula (IV): [Ph.sub.4P][Ge(SiCl.sub.3).sub.3*BBr.sub.3]. Also, methods for preparing the trichlorogermanides of formula (I), the tris(trichlorosilyl)germanide of formula (II), the tris(trichlorosilyl)germanide adduct of BBr.sub.3 of formula (IV).

Embodiments of the present disclosure describe metal-organic framework compositions comprising a pillar characterized by the formula (M.sub.bF.sub.5(O/H.sub.2O)), where M.sub.b is selected from periodic groups IIIA, IIIB, IVB, VB, VIB, and VIII; and a square grid characterized by the formula (M.sub.a(ligand).sub.x), where M.sub.a is selected from periodic groups IB, IIA, IIB, IIIA, IVA, IVB, VIB, VIIB, and VIII, ligand is a polyfunctional organic ligand, and x is 1 or more; wherein the pillaring of the square grid with the pillars forms the metal-organic framework.

Mixed ligand phosphinogold(I) complexes as anticancer agents. The gold(I) ion of the complexes is coordinated to a phosphine and a dithiocarbamate or halogen ligand. Also described are a pharmaceutical composition incorporating the phosphinogold(I) complex, a method of synthesizing the phosphinogold(I) complex, and a method of treating cancer. The phosphinogold(I) complexes exhibit potent cytotoxicity against lung, cervical, and liver cancer cells.

Halide ligand free rhenium complexes are described as well as methods for depositing rhenium-containing films. Some embodiments provide a rhenium complex with a general formula of O.sub.3ReO-M-R1R2R3, where M is a group IV element, R1 is selected from H, alkyl, alkenyl, alkynyl, an aromatic ring, or alkoxy, and R2 and R3 are each independently selected from H, alkyl, alkenyl, alkynyl, an aromatic ring, or alkoxy, or R2 and R3 join together to form a ring structure or an oxo group. Some embodiments provide a rhenium complex with a general formula of Re(NR′).sub.3(NHR″), where R′ and R″ are independently selected from H, alkyl, alkenyl, alkynyl, or an aromatic ring.